Inflammatory Markers and Resistant Depression

Centre Hospitalier Universitaire de Besancon1 site in 1 country108 target enrollmentSeptember 2016

ConditionsDepression

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Depression
Sponsor: Centre Hospitalier Universitaire de Besancon
Enrollment: 108
Locations: 1
Primary Endpoint: plasmatic concentration of Interleukin 6
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study focuses on blood inflammatory markers (pro-inflammatory cytokines, anti-inflammatory cytokines, monocytes costimulation molecules) in patients with resistant unipolar depression in comparison with non-resistant unipolar depressed patients.

Registry

clinicaltrials.gov

Start Date

September 2016

End Date

December 2018

Last Updated

9 years ago

Study Type

Interventional

Study Design

Factorial

Sex

All

Investigators

Sponsor

Centre Hospitalier Universitaire de Besancon

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•group 1: Patients with resistant MDD (at least 2 failed treatments for the current episode) ,current treatment with IRS or IRSNA,
•group 2: patients with MDD remission after response to an antidepressant treatment.

Exclusion Criteria

•comorbid somatic or psychiatric disorders: chronic or acute inflammatory diseases, previous treatment with brain stimulation for the current episode, legal protection

Outcomes

Primary Outcomes

plasmatic concentration of Interleukin 6

Time Frame: at patient inclusion

Secondary Outcomes

concentration of proinflammatory cytokine(at patient inclusion)
concentration of antiinflammatory cytokine(at patient inclusion)
plasmatic concentration of Retinoid X receptor signaling pathway(at patient inclusion)
Expression rate of monocytes costimulation molecules(at patient inclusion)
functional polymorphisms of expression genes of inflammatory proteins(at patient inclusion)